^
    Back
    Association details:
    Biomarker:ALK L1198F
    Cancer:Non Small Cell Lung Cancer
    Drug:Lorbrena (lorlatinib) (ALK inhibitor, ROS1 inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C4 – Case Studies
    New
    Source:
    N Engl J Med
    Title:

    Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F

    Excerpt:
    The ALK L1198F mutation was detected only in the lorlatinib-resistant specimen.
    DOI:
    10.1056/NEJMoa1508887